Full-Time

Software Test Analyst 2

Cellanome

Cellanome

51-200 employees

Automated platform for live single-cell assays

Compensation Overview

$75k - $90k/yr

San Diego, CA, USA

In Person

Bachelor's, Master's, PhD

Category
QA & Testing (1)
Required Skills
Software Testing
Cell Biology
Data Analysis

Get referred to Cellanome

See people who can refer or advise you

Requirements
  • Typically requires at least 2 years of relevant work experience plus a Bachelor's degree in Cell Biology, Biochemistry, Biomedical Engineering, Computer Science, a related field; or an advanced degree and no experience.
  • Solid working knowledge of cell biology, flow cytometry, fluidics, or fluorescence imaging.
  • Demonstrated ability to write clear, thorough, and maintainable test cases derived from software requirements.
  • Experience with defect tracking tools.
  • Solid understanding of SDLC.
  • Ability to communicate testing status, risks, and issues clearly to both software engineers and scientific stakeholders.
  • Demonstrated ability to perform the Essential Duties of the position with or without reasonable accommodations.
Responsibilities
  • Develop and maintain test cases and test plans for assigned instrument software areas — including UI workflows, fluidics control sequences, flow cell operations, imaging acquisition, and data analysis outputs — based on requirements and specifications.
  • Operate the instrument independently as part of test execution, configuring runs, loading reagents and flow cells, and interpreting instrument behavior to assess whether observed results reflect software issues or expected system responses.
  • Execute functional, regression, integration, and exploratory test cycles.
  • Design test scenarios that account for instrument-specific variables such as reagent types, flow cell configurations, cell concentrations, and imaging parameters.
  • Identify, document, and track defects through to resolution.
  • Participate in requirement reviews and sprint planning to provide QA perspective and flag testability risks related to fluidics, imaging, or biological variability early in the development cycle.
  • Collaborate with software engineers to understand new features or hardware changes and their implications for software testing.
  • Analyze test results to distinguish software defects from instrument variability, reagent issues, or expected biological noise.
  • Maintain organized, up-to-date test documentation across releases, including instrument configuration details and any environmental conditions relevant to test outcomes.
  • Ability to comply with personal protective equipment requirements.
Desired Qualifications
  • Hands-on laboratory experience operating flow cytometers, automated imaging platforms, or microfluidic instruments.
  • ISTQB Foundation Level certification.
  • Exposure to test management tools.
  • Exposure to image analysis concepts such as segmentation, object detection, or fluorescence quantification.
  • Familiarity with Python or other programming languages.

Cellanome provides an automated platform for live-cell phenotypic and functional assays that analyze single cells at scale. It runs high-throughput experiments that integrate with existing lab workflows, collecting multi-parameter data and allowing iterative testing under different conditions. The system emphasizes single-cell granularity, scalable data collection, and easy assay customization without major process changes. Its goal is to help life sciences, medical research, pharmaceutical, and biotech teams gain deeper cellular insights to accelerate discovery through a platform-as-a-service model.

Company Size

51-200

Company Stage

Series C

Total Funding

$276.9M

Headquarters

Foster City, California

Founded

2020

Get referred to Cellanome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Psomagen added the R3200 on March 26, 2026, validating external demand.
  • Cellanome showcased live-cell analysis marrying imaging and sequencing at AGBT 2026.
  • Cellanome raised $75.9 million on June 22, 2026, extending runway.

What critics are saying

  • 10x Genomics and other single-cell vendors already dominate adjacent workflows.
  • Cellanome still lacks proof of broad customer adoption beyond Psomagen and conferences.
  • If 2026 spending misses hardware sales, the platform becomes an expensive science project.

What makes Cellanome unique

  • Cellanome links longitudinal live-cell imaging to single-cell transcriptomics from the same cells.
  • Its CellCage micro-3D-printed enclosures isolate cells while drugs and antibodies flow.
  • R3200 captures morphology, phenotype, and RNA on identical live cells.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Stock Options

401(k) Retirement Plan

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

58%

2 year growth

0%
U.S. Securities and Exchange Commission
Jul 17th, 2026
EDGAR Filing Documents for 0000905148-26-003005

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-588010 | Film No.: 261104659

Intelligence360 News
Jul 17th, 2026
Cellanome files to raise $75.9M for live-cell imaging and single-cell transcriptomics platform

Cellanome has filed a notice with the US Securities and Exchange Commission to raise up to $75.9 million in new funding. The filing was made under Regulation D of the Securities Act of 1933, which allows companies to sell securities without full registration. The company develops technologies that combine longitudinal live-cell imaging with single-cell transcriptomics from the same cells. This approach enables scientists to capture cellular dynamics over time and connect cellular behaviour with molecular state. Researchers can access Cellanome's technology by implementing its R3200 platform in their laboratories, using its assay services, or collaborating with the company's scientists on new applications.

The Business Journals
Jan 30th, 2024
Peninsula startup with Illumina roots lands $150 million to peer deeper into cells

A Peninsula startup launched by top former Illumina execs raises $150 million to help researchers see what happens when cells dance with each other.

The Business Journals
Dec 8th, 2021
Former Illumina execs, Grail co-founder raise $21M for biotech startup

Biotech A-listers have come together to launch a new venture. What's it targeting? They're not saying.